# US 2020/0390770 A1 · Compounds and Compositions for Treating Fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390770 A1
- Document ID: US20200390770A1
- Status: Published application
- Kind: A1
- Application number: 16/954,514
- Filed: 2018-12-18
- Published: 2020-12-17
- Earliest claimed: 2017-12-18
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Anton Bennett; Jonathan Ellman; Haya Jamali; Karen S. Anderson; Elias Lolis; Denton Hoyer
- Web page: https://patentgrep.com/patent/US20200390770A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- C07D 239/70: condensed with carbocyclic rings or ring systems
- C07D 239/78: with hetero atoms directly attached in position 2
- C07D 471/04: Ortho-condensed systems
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 495/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.

## Claims

### Claim 1

A method of treating, ameliorating, or preventing a MKP-5-modulated disease or disorder in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (1a) or (1b), or a pharmaceutically acceptable salt or solvate thereof:
wherein:
Z is selected from the group consisting of NR, NC(═O)R, CH2 and O and the bond is single; or
Z is N and the bond is double;
R1 is selected from the group consisting of C1-C6 alkyl, optionally substituted phenyl and NRR;
each occurrence of R is independently selected from the group consisting of H, C1-C6 alkyl and optionally substituted phenyl;
A is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is the compound of formula (2):
wherein:
Z is selected from the group consisting of CH2 and O;
R1 is selected from the group consisting of C1-C6 alkyl, optionally substituted phenyl and NRR, where each occurrence of R is independently selected from the group consisting of H, C1-C3 alkyl and substituted or unsubstituted phenyl;
R3 is selected from the group consisting of H, C1-C6 alkyl, and C1-C3 thioether; and
R4 is selected from the group consisting of H and COOR5, where R5 is selected from the group consisting of H and C1-C6 alkyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the aryl or heteroaryl is substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 thioalkyl, C(═O)OH, C(═O)OC1-C6 alkyl, cyano and halo.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound has a Ki≤100 μM against MKP-5.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound binds to an allosteric site of MKP-5.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of 3,3-dimethyl-1-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one; 1-((5,6-dihydrobenzo[h]quinazolin-2-yl)thio)-3,3-dimethylbutan-2-one; N,N-dimethyl-2-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)acetamide; N-ethyl-N-methyl-2-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)acetamide; 1-((9-fluoro-5,6-dihydrobenzo[h]quinazolin-2-yl)thio)-3,3-dimethylbutan-2-one; 1-((6H-isochromeno[4,3-d]pyrimidin-2-yl)thio)-3,3-dimethylbutan-2-one; 1-(2,4-dichlorophenyl)-2-((4-(3,4-dimethylthieno[2,3-b]thiophen-2-yl)pyrimidin-2-yl)thio)ethan-1-one; 1-((5,6-dihydrothieno[2,3-h]quinazolin-2-yl)thio)-3,3-dimethylbutan-2-one; 3,3-dimethyl-1-(pyrimido[5,4-c]quinolin-2-ylthio)butan-2-one; and 1-((6-acetyl-5,6-dihydropyrimido[5,4-c]quinolin-2-yl)thio)-3,3-dimethylbutan-2-one; and 3,3-dimethyl-1-((9-propyl-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound is administered as part of a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier.

### Claim 9 (depends on 1)

The method of claim 1, wherein the MKP-5 modulated disease or disorder is a fibrotic disease or disorder.

### Claim 10 (depends on 9)

The method of claim 9, wherein the MKP-5 modulated disease or disorder is selected from the group consisting of dystrophic muscle disease, a cardiac or vascular disease, idiopathic pulmonary fibrosis, and any combinations thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 12 (depends on 1)

The method of claim 1, wherein the MKP-5 inhibitor is administered to the mammal by at least one route selected from the group consisting of nasal, inhalational, topical, oral, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intratracheal, otic, intraocular, intrathecal, and intravenous routes.

### Claim 13 (depends on 1)

The method of claim 1, further comprising administering to the mammal at least one additional agent that treats, ameliorates, or prevents the MKP-5 modulated disease or disorder in the mammal.

### Claim 14 (depends on 13)

The method of claim 13, wherein the inhibitor and at least one additional agent are coformulated.

### Claim 15

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 16

A kit for preventing, ameliorating, or treating a MKP-5 modulated disease or disorder in a mammal, the kit comprising a MKP-5 inhibitor, optionally an applicator, and an instructional material for use thereof, wherein the instructional material recites the amount of, and frequency with which, the MKP-5 inhibitor is to be administered to the mammal to treat or prevent the MKP-5 modulated disease or disorder.

### Claim 17

A method of determining if a test compound is a MKP-5 inhibitor, the method comprising:
contacting a test compound with (i) a substrate peptide comprising the amino acid sequence pThr-Gly-pTyr and (ii) a catalytic polypeptide comprising and/or consisting of the catalytic domain of MKP-5, or an active fragment thereof, thus forming a composition;
measuring MKP-5 activity in the composition; and
comparing the MKP-5 activity in the composition to a control;
thereby determining if the test compound is a MKP-5 inhibitor.

### Claim 18 (depends on 17)

The method of claim 17, wherein the substrate peptide comprises the amino acid sequence Asp-Asp-Glu-Nle-pThr-Gly-pTyr-Val-Ala-Thr-Arg (pTpY, SEQ ID NO:3).

### Claim 19 (depends on 17)

The method of claim 17, wherein the measuring of MKP-5 activity comprises measuring any change in inorganic free phosphate in the composition.
